Abstract Library

#2993 Proposal of New Imaging Criteria for Evaluating the Response of Liver Metastases to Systemic Treatments in Digestive Neuroendocrine Tumors (NET) as an Alternative to RECIST 1.1

Introduction: RECIST 1.1 criteria have been challenged for the evaluation of treatment response in NET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: de Mestier L, Dromain C, Lamarca A, La Salvia A, Op de Beeck B,

Keywords: imaging criteria, response evaluation, CT scan,

#1675 Abdominal Obesity, Fasting Glucose and Metabolic Syndrome Are Risk Factors for Well Differentiated Digestive Neuroendocrine Tumors

Introduction: Digestive NETs(DNETs)`s incidence has increased last 40 years. Visceral obesity and metabolic syndrome (MetSyn) were recently reported to be associated with several cancers, although not so far with DNET.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Santos A, Santos A, Castro C, Raposo L, Torres I,

Keywords: neuroendocrine tumors, metabolic syndrome, visceral obesity ,

#900 Renal Effects of Streptozocin: Preliminary Results of the STREPTOTOX Study

Introduction: Based on old studies, Streptozocin (STZ) is known to have some renal toxicity.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Mitry E

Authors: Mitry E, Brixi H, Lecomte T, Lombard-Bohas C, Seitz J,

Keywords: digestive neuroendocrine tumors, streptozotocin, nephrotoxicity, chemotherapy,

#896 Grading of Metastases in Digestive Neuroendocrine Tumors (NET): Interest for Clinical Management?

Introduction: Therapeutic strategy of NETs is highly dependent on tumor classification according to the WHO system. NETs are frequently classified based on the histological characteristics of the primary tumor associated with the ENETS grading, even for patients with metastases.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Dumars C

Authors: Dumars C, Foubert F, Touchefeu Y, Regenet N, Senellart H,

Keywords: NET, grading,

#475 Methylguanine DNA Methyl Transferase (MGMT) Expression Predicts Response to Temozolamide in Patients with Digestive Neuroendocrine Tumors (NETs)

Introduction: Temozolomide (TEM) is an oral drug with encouraging results in pancreatic NETs (PNETs). MGMT tumor deficiency seems to be correlated with higher treatment efficacy.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Hentic O, Cros J, Rebours V, Zappa M, Maire F,

Keywords: neuroendocrine tumor, treatment, temozolomide, MGMT,